TITLE

Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors

AUTHOR(S)
Maeda, Yasuhiro; Okamoto, Atsushi; Kawaguchi, Shin-ichiro; Konishi, Akiko; Yamamoto, Kenta; Eguchi, Go; Kanai, Yoshitaka; Yamaguchi, Terufumi
PUB. DATE
November 2017
SOURCE
Acta Haematologica;Nov2017, Vol. 138 Issue 3, p140
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the improved drug adherence in patients with chronic myeloid leukemia (CML) by switching to second-generation tyrosine kinase inhibitors (TKI). It compared the drug adherence rates from Imatinib (IM) to TKI nilotinib (NILO). It notes that adherence is a critical factor for improving survival rates in patients with CML treated with TKI.
ACCESSION #
126499268

 

Related Articles

  • Switching-On Adherence in Chronic Myeloid Leukemia. Leader, Avi; Raanani, Pia // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p138 

    The authors reflect on the clinical challenge in the management of chronic myeloid leukemia (CML) due to patients' nonadherence to tyrosine kinase inhibitors (TKI). They cite the retrospective study by Maeda et al. that suggests that switching medications from imatinib to nilotinib may resolve...

  • Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Santoleri, Fiorenzo; Lasala, Ruggero; Ranucci, Elena; La Barba, Gaetano; Di Lorenzo, Roberto; Vetrò, antonio; Di Bartolomeo, Paolo; Costantini, alberto // Acta Haematologica;Jun2016, Vol. 136 Issue 1, p45 

    Objective: Adherence to tyrosine kinase inhibitor treatment is a significant factor in the achievement of a good clinical response in chronic myeloid leukemia (CML). The aim of this retrospective study is to investigate 1- and 2-year medication adherence to imatinib treatment, linking adherence...

  • Atypical Chronic Myeloid Leukaemia with CD117-Positive Blast Cells Treated with Imatinib: A Report of Two Cases. Breccia, Massimo; Russo, Eleonora; De Propris, Maria Stefania; Frustaci, Annamaria; Alimena, Giuliana // Acta Haematologica;Oct2006, Vol. 116 Issue 3, p211 

    The article describes two cases of chronic myeloid leukemia (CML) treated with imatinib mesylate on the basis of the bright expression of c-kit on blast cells. The first case involves a 53-year-old woman who was admitted to a hospital due to itchiness and splenomegaly. The second case involves a...

  • Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Oyekunle, Anthony; Klyuchnikov, Evgeny; Ocheni, Sunday; Kröger, Nicolaus; Zander, Axel R.; Baccarani, Michele; Bacher, Ulrike // Acta Haematologica;2011, Vol. 126 Issue 1, p30 

    Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell transplantation (HSCT) scene in CML has changed dramatically. The number of patients receiving HSCT in first chronic...

  • Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort. de Almeida, Maria H.; Pagnano, Katia B.B.; Vigorito, Afonso C.; Lorand-Metze, Irene; de Souza, Carmino A. // Acta Haematologica;2013, Vol. 130 Issue 1, p16 

    The introduction of oral tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes in chronic myeloid leukemia (CML) patients. However, treatment success is directly related to good long-term adherence. Adherence to TKI therapy was evaluated in 137 CML patients over a period of 1...

  • Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era? Trela, Ewelina; Glowacki, Sylwester; Błasiak, Janusz // ISRN Otolaryngology;2014, p1 

    Chronic myeloid leukemia (CML) results from the clonal expansion of pluripotent hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a reciprocal translocation of the ABL1 gene to the BCR gene. The BCR/ABL protein displays a constitutive tyrosine kinase activity and...

  • Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy. Ferreira, aline Fernanda; de Oliveira, Gislane L.V.; Tognon, Raquel; Collassanti, Maria Dulce S.; Zanichelli, Maria aparecida; Hamerschlak, Nelson; de Souza, ana Maria; Covas, Dimas Tadeu; Kashima, Simone; de Castro, Fabiola attie // Acta Haematologica;May2015, Vol. 133 Issue 4, p354 

    Background/Aims: We investigated the effects of tyrosine kinase inhibitors (TKIs) on the expression of apoptosis-related genes (BCL-2 and death receptor family members) in chronic myeloid leukemia (CML) patients. Methods: Peripheral blood mononuclear cells from 32 healthy subjects and 26 CML...

  • CD117 (c-kit) Expression on CD34+ Cells Participates in the Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia in the First Chronic Phase. Dybko, Jaroslaw; Haus, Olga; Jaźwiec, Bożena; Urbaniak, Joanna; Woźniak, Mieczysław; Kaczmar-Dybko, agnieszka; Urbaniak-Kujda, Donata; Kapelko-Slowik, Katarzyna; Kuliczkowski, Kazimierz // Acta Haematologica;Aug2014, Vol. 132 Issue 2, p166 

    Background: Chronic myeloid leukemia (CML) biology seemed to be perfectly explored especially at the beginning of the tyrosine kinase inhibitors era. Later years with imatinib and second-generation tyrosine kinase inhibitors showed a variety of resistance mechanisms and it became obvious that...

  • Growth Arrest of BCR-ABL Positive Cells with a Sequence-Specific Polyamide-Chlorambucil Conjugate. Chou, C. James; O'Hare, Thomas; Lefebvre, Sophie; Alvarez, David; Tyner, Jeffrey W.; Eide, Christopher A.; Druker, Brian J.; Gottesfeld, Joel M. // PLoS ONE;2008, Vol. 3 Issue 10, p1 

    Chronic myeloid leukemia (CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective inhibitor of the Bcr-Abl tyrosine kinase, has...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics